Holders who exercise their Warrants will receive 1.5 shares of
Any Warrants that are not validly exercised by
We highly encourage holders of Warrants to allow sufficient time for their financial institutions to process their Warrants prior to the deadline of
Details of the Warrant Distribution and Bonus Share Program
On or around
Each Warrant entitles the holder to purchase, at the holder's sole and exclusive election, one share of
The Bonus Share Fraction entitles a holder to receive an additional 0.5 of a share of common stock for each Warrant exercised (the 'Bonus Share Fraction') without payment of any additional exercise price. The right to exercise Warrants (and thereby receive the Bonus Share Fraction) will end at
Prior to the Redemption Date, Warrant holders may cash-exercise their Warrants, or they may sell their Warrants on the open market.
As noted above, because the Company has elected to redeem the Warrants,
For any further details regarding the Warrant distribution and the terms of the Warrants, including the provisions regarding redemption of the Warrants, see the Current Report on Form 8-K filed by the Company on
About
Contact:
Tel: (512) 501-2450
Email: ESchoen@CassavaSciences.com
Cautionary Note Regarding Forward-Looking Statements
This Press Release and the Q&A referenced in it contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: the development of new treatment options for people with Alzheimer's disease; the long-term success of the Company; the Company's ability to raise additional capital while protecting stockholders from excessive dilution; the design, scope, completion, intended purpose, or future results of our warrant distribution; any expected clinical results of our on-going Phase 3 studies of simufilam in Alzheimer's disease; the treatment of people with Alzheimer's disease dementia; the safety or efficacy of simufilam in people with Alzheimer's disease dementia; expected cash use of proceeds from the warrant distribution; the trading price and liquidly of the warrants; the continued development of an acceptable trading market for the warrants; the actual redemption of the Warrants on the Redemption Date; whether the distribution of a warrant was a taxable event; comments made by our employees regarding the warrant distribution, simufilam, and potential benefits, if any, of our product candidates. These statements may be identified by words such as 'may,' 'anticipate,' 'believe,' 'could,' 'expect,' 'forecast,' 'intend,' 'plan,' 'possible,' 'potential,' and other words and terms of similar meaning.
Simufilam is our investigational product candidate. It is not approved by any regulatory authority in any jurisdiction and its safety, efficacy or other desirable attributes have not been established in patients.
Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Clinical results and analyses of our previous studies should not be relied upon as predictive of Phase 3 studies or any other study. Our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
Forward looking statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of the warrant distribution on our business operations, and including those described in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the year ended
Contact:
Tel: (512) 501 2444
(C) 2024 Electronic News Publishing, source